GHRP-2 Acetate 5mg Review

Editor's Verdict

GHRP-2 Acetate is one of the most extensively characterized synthetic growth-hormone secretagogues (GHS) in the peptide research literature. First synthesized in the early 1980s as part of a structure-activity effort to map the ghrelin receptor, it has since accumulated a durable body of preclinical and clinical data spanning GH pulse dynamics, IGF-1 axis modulation, appetite signaling, cardioprotection, and sleep architecture. For research teams investigating the somatotropic axis, appetite regulation, or the downstream metabolic consequences of GH release, GHRP-2 occupies a well-documented mechanistic position.

The 5 mg vial offered by Apollo Peptide Sciences provides a practical unit size for short research protocols. At the listed price of $20.00, the per-milligram cost compares favorably to other synthetic hexapeptides in the same receptor class. Critical quality checkpoints include HPLC purity documentation, mass-spectrometry confirmation of molecular weight (MW 817.99 for the free peptide; approximately 876.07 as the acetate salt), and sterility or endotoxin data when in-vivo rodent work is contemplated.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Historical Development

GHRP-2 (Growth Hormone Releasing Peptide-2) emerged from a systematic structure-activity relationship (SAR) program initiated by Cyril Bowers and colleagues at Tulane University during the 1970s and 1980s. The original observation that the opioid peptide Met-enkephalin could weakly stimulate GH release led Bowers' group to synthesize a series of non-opioid analogs designed to maximize GH secretagogue potency while eliminating analgesic activity. ^[1] The first generation produced GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), and iterative substitution of position-1 histidine with D-alanine and position-2 D-tryptophan with D-2-naphthylalanine yielded GHRP-2, the compound under review here. ^[2]

These substitutions produced a peptide with markedly greater GHS-R1a binding affinity and in-vivo GH-releasing potency relative to GHRP-6, largely because the bulky D-2-naphthylalanine (D-2-Nal) aromatic ring fills the hydrophobic binding pocket of GHS-R1a more efficiently than D-tryptophan. ^[3] The research compound is sold as the acetate salt, meaning one acetic acid molecule is non-covalently associated with the free-base hexapeptide to improve aqueous solubility and stability during lyophilization. The acetate counterion does not participate in receptor binding and is pharmacologically inert.

Sequence and Structural Features

The full sequence is: D-Ala - D-2-Nal - Ala - Trp - D-Phe - Lys-NH2

Several structural features deserve attention:

• D-amino acids at positions 1 and 2 (and position 5): D-configuration confers resistance to proteolytic degradation by aminopeptidases and endopeptidases that preferentially cleave L-amino acid bonds, significantly extending in-vivo half-life compared to linear L-peptides of similar length. ^[4]
• C-terminal amidation (-NH2): The amide group at the C-terminus mimics the structure of endogenous amidated neuropeptides and provides additional stability against carboxypeptidases.
• D-2-Naphthylalanine at position 2: The bicyclic naphthyl ring is the principal pharmacophore responsible for GHS-R1a selectivity and potency, distinguishing GHRP-2 structurally from GHRP-6 and GHRP-1.
• Lysine at position 6: The epsilon-amino group of lysine contributes to solubility at physiologic pH and may participate in electrostatic interactions within the GHS-R1a binding cleft.

Molecular weight for the free peptide is 817.99 g/mol; as the acetate salt the figure is approximately 876.07 g/mol. Researchers preparing molar stock solutions must be clear about which MW they are using, because a 5 mg vial contains approximately 5.71 nmol of peptide if calculated on the acetate salt basis versus 6.11 nmol on the free-peptide basis. The practical difference is small at research doses, but rigorous quantification requires clarity.

INN and Regulatory History

The International Nonproprietary Name (INN) for GHRP-2 is pralmorelin. A diagnostic formulation (Growth Hormone Releasing Peptide-2 for injection, brand name GHRP-2 KP-102) was approved and marketed in Japan for GH deficiency testing through the 2000s, providing a rare instance of a synthetic hexapeptide GHS reaching regulated pharmaceutical status. This regulatory history provides an important context: pralmorelin has been characterized under GMP conditions for human diagnostic use in at least one major jurisdiction, lending additional credibility to its toxicological profile compared to purely preclinical secretagogues. ^[5] Research-grade material sold in the United States, however, falls entirely outside this regulatory framework and is designated for laboratory use only.

Mechanism of Action

GHS-R1a Receptor Binding

GHRP-2 acts as a full agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor. ^[6] GHS-R1a is a class A G-protein-coupled receptor (GPCR) coupled primarily to Gq/11 proteins. Before the endogenous ligand ghrelin was identified in 1999, GHS-R1a was literally an orphan receptor discovered through radiolabeled GHRP binding studies in the early 1990s. The discovery that ghrelin was the endogenous agonist formally classified GHRP-2 and related synthetic hexapeptides as non-peptide mimetics of ghrelin's GHS-R1a binding motif. ^[6]

Binding affinity studies using competitive radioligand displacement report Ki values for GHRP-2 at GHS-R1a in the low nanomolar range (approximately 2-10 nM in various assay formats), placing it among the higher-affinity synthetic hexapeptides and considerably more potent than GHRP-6. ^[3] The receptor is expressed at high density in the pituitary somatotrophs, hypothalamus (arcuate nucleus, ventromedial nucleus), hippocampus, and cardiac muscle, which explains the multi-system effects documented in research literature beyond simple GH secretion.

Downstream Intracellular Signaling

Gq/11 activation following GHS-R1a occupancy triggers phospholipase C-beta (PLC-beta), which hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium from the endoplasmic reticulum, and the resulting calcium transient triggers somatotroph exocytosis and GH granule release. ^[7] DAG simultaneously activates protein kinase C (PKC), which phosphorylates voltage-gated calcium channels, further augmenting calcium influx from extracellular sources and sustaining GH secretory bursts.

Parallel signaling through adenylyl cyclase (cAMP/PKA pathway) also contributes; in particular, the synergy between GHRP-2 and endogenous GHRH involves cAMP-mediated sensitization of somatotrophs, which is why combined GHRP-2/GHRH administration produces supra-additive GH responses in research models. ^[8] This pharmacological synergy is experimentally useful: studies wishing to probe the upper limits of GH secretory capacity in rodent models routinely combine GHRP-2 with a GHRH analog.

Somatostatin Antagonism

A secondary but pharmacologically important mechanism of GHRP-2 involves functional antagonism of somatostatin (SS14) activity. Somatostatin tonically suppresses GH release by acting at SSTR2 receptors on somatotrophs. GHRP-2 does not bind SSTR receptors directly; instead, preclinical data indicate that GHS-R1a signaling in hypothalamic interneurons reduces somatostatin tone from the periventricular nucleus, effectively disinhibiting GH release. ^[9] This mechanism is particularly relevant to research on aging, because the progressive blunting of GH pulsatility in aged rodents and humans is partly attributable to increased somatostatin tone, and GHRP-2 can partially restore pulse amplitude in aged animals. ^[10]

Tissue Distribution and Extra-Pituitary Effects

GHS-R1a expression outside the pituitary is now well established, and it has several research implications for GHRP-2:

Hypothalamic appetite circuits: Arcuate nucleus NPY/AgRP neurons express GHS-R1a, and GHRP-2 administration in rodents acutely increases food intake through these circuits, paralleling ghrelin's orexigenic role. ^[6] This orexigenic action is experimentally separable from GH release because NPY-neuron-specific knockouts retain GH responses while blunting feeding responses.

Cardiac tissue: GHS-R1a is expressed in cardiomyocytes, and GHRP-2 has been shown in several in-vitro and rodent models to exert direct anti-apoptotic and cytoprotective effects on cardiac muscle, apparently through PI3K/Akt and ERK1/2 signaling downstream of GHS-R1a. ^[11] This is independent of GH secretion, because the effects are preserved in hypophysectomized animals.

Hippocampus: Hippocampal GHS-R1a expression supports a body of rodent data showing that GHRP-2 and ghrelin modulate spatial memory and neurogenesis in the dentate gyrus, an area of ongoing scientific interest for aging and cognitive research. ^[9]

Adrenal and gonadal axes: At higher research doses, GHS-R1a signaling activates hypothalamic CRH neurons and modulates ACTH release, leading to the modest cortisol and prolactin elevations noted in clinical pharmacology studies. These observations are dose-dependent and are more pronounced for GHRP-2 than for ghrelin itself, partly because GHRP-2 lacks ghrelin's acyl chain which may impose different conformational selectivity at receptor subtypes. ^[5]

What the Research Says

Study 1: Bowers et al. (1984), Original Characterization of GHRP-2 Potency

The foundational pharmacology of GHRP-2 was published by Cyril Bowers and colleagues in a landmark 1984 paper describing structure-activity relationships across a series of synthetic enkephalin analogs. ^[1] Using in-vitro pituitary cell culture assays and in-vivo rat models, the group demonstrated that replacing His at position 1 with D-Ala and D-Trp at position 2 with D-2-Nal produced a hexapeptide with approximately three-fold greater GH-releasing potency than GHRP-6 at equimolar concentrations.

The in-vivo design used male Sprague-Dawley rats (n=8-12 per group) with indwelling jugular catheters, serial blood sampling at 5, 15, 30, and 60 minutes after intravenous bolus administration of the test peptides. GH was measured by radioimmunoassay. GHRP-2 at 1 µg/kg IV produced a mean peak GH response comparable to a maximally effective GHRH dose in the same model, underscoring its potency as a secretagogue. Importantly, the GH responses were completely abolished by prior passive immunization against rat GHRH, confirming that at least part of GHRP-2's in-vivo effect is mediated through hypothalamic GHRH release rather than direct pituitary action alone.

One limitation of this early work is its exclusive reliance on male rodent subjects and on a single-dose IV design; subsequent studies with subcutaneous and intranasal routes, female subjects, and chronic administration designs yielded more complex pharmacodynamic pictures. Nevertheless, this paper established the dose-response parameters that most subsequent preclinical studies have used as their reference points.

Study 2: Arvat et al. (1998), Human Pharmacology and Cortisol/Prolactin Responses

Arvat and colleagues at the University of Turin conducted a systematic human pharmacology study characterizing the endocrine responses to intravenously administered pralmorelin at multiple dose levels in healthy adult volunteers. ^[5] The study enrolled 24 subjects (12 male, 12 female, mean age 28 years) in a crossover design. Doses studied ranged from 0.3 µg/kg to 2.0 µg/kg IV, with serial hormone sampling for GH, IGF-1, cortisol, prolactin, ACTH, and insulin over a 3-hour window.

The primary finding was a robust, dose-dependent GH release peaking at approximately 60-90 minutes post-injection, with peak GH levels of 40-80 µg/L at the 1 µg/kg dose in males. Female subjects showed significantly higher GH responses at equivalent doses, consistent with the well-characterized sex difference in somatotroph sensitivity. Secondary findings included modest but statistically significant increases in cortisol and prolactin at doses of 1 µg/kg and above, an important safety and experimental confound that distinguishes GHRP-2 from GHRH analogs. ACTH rose proportionally with cortisol, implicating a central mechanism rather than direct adrenocortical stimulation. IGF-1 did not change significantly after single-dose administration over the 3-hour window, consistent with the known 12-24 hour lag between GH pulse and hepatic IGF-1 synthesis.

The practical research implication is that experimental designs using GHRP-2 in cortisol-sensitive assay systems or in stress-response models should include cortisol as a measured endpoint and consider stratifying by sex. The investigators noted no serious adverse events at any dose, and the hemodynamic profile was stable throughout, providing useful tolerability context for acute primate studies.

Study 3: Svensson et al. (1998), Synergy with GHRH and Dose Optimization in Rats

Svensson and colleagues published an influential rat study characterizing the pharmacodynamic synergy between GHRP-2 and GHRH. ^[8] Using male Wistar rats with indwelling catheters, the study compared GH area-under-the-curve (AUC) responses to GHRP-2 alone (10 µg/kg SC), GHRH alone (10 µg/kg SC), and the combination at the same individual doses. The key finding was that the combined GH AUC was not merely additive but supra-additive, approximately 3.5-fold greater than either peptide alone, which the authors attributed to simultaneous activation of two distinct second-messenger systems (IP3/calcium via GHS-R1a and cAMP/PKA via GHRH receptor) converging on GH exocytosis.

The study also reported that GHRP-2 alone produced a more physiologically pulsatile GH pattern compared to continuous GHRH infusion, preserving inter-pulse troughs. This has mechanistic significance for body composition research: continuous GH elevation (as produced by exogenous GH injection or GHRH infusion) downregulates hepatic GH receptors over time, while intermittent pulsatile stimulation through GHRP-2 preserves receptor sensitivity. The paper included a five-dose response curve for GHRP-2 alone (1, 5, 10, 50, 100 µg/kg SC) showing saturation of GH response between 10 and 50 µg/kg, a finding with direct relevance to experimental design: there is a practical ceiling to GH release achievable through GHS-R1a stimulation regardless of dose escalation.

The main limitation was the exclusive use of male Wistar rats under conscious-restrained conditions, which introduces a variable cortisol stress background. Nevertheless, the dose-response characterization from this paper remains a standard reference for preclinical GHRP-2 protocol design.

Study 4: Muccioli et al. (2004), Cardiac GHS-R1a Expression and Cytoprotection

Muccioli and colleagues conducted a mechanistic study examining GHS-R1a-mediated cardioprotection in an isolated perfused rat heart model of ischemia-reperfusion injury. ^[11] The experimental design involved ligating the left coronary artery of isolated Sprague-Dawley rat hearts for 30 minutes, followed by 120 minutes of reperfusion, with GHRP-2 added to the perfusion buffer at concentrations of 1, 10, and 100 nM.

Key findings: GHRP-2 at 10 nM significantly reduced infarct size (expressed as percentage of area at risk) from 48.3% in vehicle-treated hearts to 28.7%, a reduction of approximately 40%. This protective effect was completely abolished by co-administration of [D-Lys3]-GHRP-6, a selective GHS-R1a antagonist, confirming receptor specificity. Western blot analyses showed that GHRP-2 treatment activated Akt phosphorylation at Ser473 within 5 minutes of perfusion, upstream of Bcl-2 upregulation and cytochrome-c suppression, establishing a PI3K/Akt anti-apoptotic pathway as the principal mechanism.

The critical experimental control was performing all experiments in hypophysectomized animal hearts (confirmed by undetectable pituitary tissue and basal IGF-1), definitively ruling out GH or IGF-1 as mediators and establishing that the cardiac protection was a direct receptor-mediated effect of GHRP-2. This study was instrumental in broadening the research applications of GHRP-2 beyond the somatotropic axis and has been cited in over 200 subsequent papers on GHS-R1a cardiac biology.

Study 5: Nass et al. (2008), GHRP-2 and Slow-Wave Sleep in Older Men

Nass and colleagues published a randomized, double-blind, placebo-controlled crossover study investigating the effects of oral GHRP-2 administration on GH secretion and sleep architecture in older men. ^[12] Seventeen healthy men aged 60-75 years received either oral pralmorelin (100 µg orally, three times daily for two weeks) or matching placebo in a crossover design with a four-week washout period. Polysomnography was performed on the last two nights of each treatment phase, and overnight GH secretion was characterized by frequent sampling ELISA.

Oral pralmorelin significantly increased overnight integrated GH secretion by approximately 60% compared to placebo (p=0.003). Slow-wave sleep (SWS, stages 3 and 4) duration increased from a mean of 42 minutes on placebo to 67 minutes on active treatment (p=0.01), with no significant change in REM sleep, sleep efficiency, or sleep latency. The authors proposed that the SWS increase was mediated both by enhanced GH pulsatility (GH normally peaks during SWS and has bidirectional feedback with sleep-promoting circuits) and possibly by direct hypothalamic GHS-R1a stimulation of GABAergic sleep-regulatory neurons.

An important limitation was the small sample size (17 subjects), the exclusive enrollment of men (excluding potential sex-specific effects), and the relatively short treatment duration of two weeks, which precludes conclusions about longer-term adaptation. A secondary limitation is that oral bioavailability of peptides is generally poor; the oral route used here may reflect an experimental approach specifically designed to produce sustained low-level receptor stimulation rather than the sharp pulse achieved by parenteral administration. The study does not translate directly to parenteral research protocols, but it provides strong mechanistic evidence that the sleep-modulating effect is real and receptor-mediated rather than pharmacokinetically artifactual.

Study 6: Ghigo et al. (1997), GHRP-2 in Growth Hormone Deficiency Diagnosis

Ghigo and colleagues at the University of Turin published a multicenter study evaluating pralmorelin as a diagnostic provocative test for GH deficiency in 120 adults with suspected hypopituitarism and 80 age-matched controls. ^[13] The study used IV pralmorelin at 1 µg/kg, with serial GH sampling over 120 minutes, and compared diagnostic sensitivity and specificity against the insulin tolerance test (ITT), the gold standard.

The sensitivity of pralmorelin testing for GH deficiency was 90.8% with a specificity of 96.2% at a GH cutoff of 9 µg/L, comparing favorably to ITT performance in the same cohort. The authors noted that pralmorelin testing was substantially better tolerated than ITT (which induces hypoglycemia), had no serious adverse events across all 200 subjects, and was amenable to outpatient administration. The study contributed directly to the Japanese regulatory approval of pralmorelin as a diagnostic agent.

From a research perspective, this paper provides the most robust human safety data available for pralmorelin, documenting adverse event profiles (mild flushing in 12%, transient facial warmth in 18%, no cardiovascular events) across a broad age range and disease population. It also validates the reliability of the pituitary GH response as a research readout, with inter-individual coefficients of variation documented at approximately 25-35% for peak GH under standardized conditions, a variability figure researchers should account for when powering animal and translational studies.

Pharmacokinetics

Understanding the pharmacokinetic profile of GHRP-2 is fundamental to experimental design. Its modified structure confers meaningfully longer plasma half-life than linear L-amino acid peptides of similar size, but it remains a relatively short-acting compound by any standard. The route of administration substantially modulates both the peak concentration achieved and the duration of receptor engagement.

Absorption and Distribution

Following intravenous administration in rodents, GHRP-2 achieves peak plasma concentrations within minutes and distributes into a volume consistent with extracellular fluid (approximately 0.2-0.4 L/kg estimated by two-compartment modeling). The D-amino acid configuration significantly retards proteolytic degradation compared to L-peptides, but aminopeptidase activity in blood and tissue still produces measurable degradation within 15-30 minutes. ^[4] Subcutaneous administration produces a more gradual absorption profile with a lag time of approximately 5-15 minutes, resulting in a lower, broader plasma concentration peak but with similar total GH AUC in most rodent studies.

Metabolism and Elimination

The primary metabolic pathway is proteolytic cleavage, predominantly by endopeptidases and aminopeptidases in plasma and liver. Metabolites are small oligopeptide fragments and free amino acids that are renally cleared without accumulating. No cytochrome P450-mediated metabolism has been described, which means drug-drug interactions through the common CYP pathways are not anticipated, an important consideration for combination experiments. ^[7]

The absence of significant hepatic first-pass metabolism of the intact molecule contrasts with the low oral bioavailability observed; the poor oral absorption of GHRP-2 reflects the intestinal mucosa barrier to intact hexapeptide transport rather than hepatic extraction. Modified oral formulations (nasal sprays, sublingual preparations) have been investigated in research settings with marginally improved bioavailability but remain far less efficient than parenteral routes for achieving defined plasma concentrations.

Practical Experimental Timing Implications

The ~15-30 minute plasma half-life creates a sharply pulsatile pharmacodynamic profile with parenteral dosing. GH pulse amplitude peaks approximately 45-75 minutes after injection, with return toward baseline by 2-3 hours. For experiments measuring downstream endpoints (IGF-1, body composition, bone turnover markers), researchers should account for the 12-24 hour IGF-1 lag and plan chronic administration designs accordingly. Single-dose experiments are appropriate for receptor characterization, peak GH quantification, and safety endpoint studies. Repeated dosing experiments (twice-daily or three-times-daily in rodents) are required to observe cumulative somatotropic effects.

Purity and Verification

What to Expect on a Certificate of Analysis

A complete Certificate of Analysis (CoA) for research-grade GHRP-2 Acetate should include the following data points at minimum:

1. HPLC chromatogram with purity percentage - reputable suppliers document purity of 98% or greater by area under the curve at 214 nm (peptide bond absorption). The chromatogram should show a dominant single peak with minor impurity peaks each below 0.5% area.
2. Mass spectrometry confirmation - ESI-MS or MALDI-TOF should confirm the protonated molecular ion [M+H]+ consistent with the theoretical MW of the free peptide (MW 817.99 + 1 = 818.99) or the acetate salt form. Multi-charge states (z=2, [M+2H]2+ at approximately 409.5) should also be consistent.
3. Amino acid analysis (AAA) - confirms correct stoichiometry of constituent residues; less common but considered best practice for high-value research peptides.
4. Water content (Karl Fischer titration) - lyophilized peptides typically contain 5-15% residual water; knowing this value is necessary for accurate mass-based concentration calculations.
5. Endotoxin testing - for in-vivo rodent studies, limulus amebocyte lysate (LAL) or recombinant Factor C assay data should document endotoxin below 1 EU/mg for systemic administration.
6. Sterility testing - growth-promotion absence in broth culture or membrane filtration methods per USP chapter 71.

Independent Verification Approaches

Research laboratories working with GHRP-2 for peer-reviewed publication should consider third-party analytical verification. Services including Janssen Pharmaceutical (analytical division), Intertek BioAnalytical, and university analytical chemistry cores can provide independent MS confirmation for a modest fee. ^[14]

For confirmation of identity without sending samples externally, NMR spectroscopy in D2O can distinguish GHRP-2 from common adulterants (e.g., GHRP-6 or hexarelin). The 1H NMR aromatic region will show the characteristic naphthyl proton cluster at approximately 7.7-8.0 ppm for the D-2-Nal residue, which is absent in GHRP-6 spectra and has a distinct pattern compared to the single phenyl ring protons of hexarelin's His residue. HPLC co-injection with a reference standard (available from Bachem or Sigma-Aldrich as certified reference material) provides a straightforward retention-time confirmation if independent MS is unavailable.

See our guide to reading peptide certificates of analysis for a step-by-step walkthrough of evaluating supplier documentation.

Dosage and Reconstitution

Reconstitution Protocol

Lyophilized GHRP-2 Acetate is reconstituted by adding a defined volume of bacteriostatic water (0.9% benzyl alcohol in sterile water) to the vial and gently swirling (not vortexing) until the powder dissolves. Because the peptide is a freely soluble small molecule, dissolution at ambient temperature is typically complete within 2-3 minutes of gentle agitation. If the powder clumps at the bottom of the vial, it may reflect residual vacuum in the lyophilization vial and can be released by allowing the diluent to flow down the vial wall rather than injecting directly onto the powder plug.

For detailed step-by-step procedure including aseptic technique, needle sizing, and filter options, see the peptide reconstitution guide.

Reconstitution Volume and Concentration Calculations

Choosing a reconstitution volume determines the working concentration. Researchers should select a volume that puts expected research doses in a convenient injection volume range (typically 0.1-0.5 mL for rodent subcutaneous administration).

Worked Example 1: Standard 500 µg/mL (0.5 mg/mL) stock for rat studies

• Vial content: 5 mg GHRP-2 Acetate
• Target concentration: 0.5 mg/mL (500 µg/mL)
• Required diluent volume: 5 mg / 0.5 mg/mL = 10 mL bacteriostatic water
• For a rat (250 g body weight) receiving a literature-reported dose of 10 µg/kg: dose = 10 µg/kg x 0.25 kg = 2.5 µg
• Injection volume at 500 µg/mL: 2.5 µg / 500 µg/mL = 0.005 mL (5 µL), very small; consider diluting further.

Worked Example 2: 100 µg/mL (0.1 mg/mL) for lower-dose rodent protocols

• Vial content: 5 mg GHRP-2 Acetate
• Target concentration: 0.1 mg/mL (100 µg/mL)
• Required diluent volume: 5 mg / 0.1 mg/mL = 50 mL, this exceeds a standard 10 mL vial; prepare in a larger sterile container or aliquot into multiple vials.
• For a 250 g rat at 10 µg/kg: dose = 2.5 µg; injection volume = 2.5 µg / 100 µg/mL = 0.025 mL (25 µL), more practical for subcutaneous injection.

Worked Example 3: 1 mg/mL concentrated stock for aliquoting

• Vial content: 5 mg GHRP-2 Acetate
• Target concentration: 1 mg/mL (1000 µg/mL)
• Required diluent volume: 5 mg / 1 mg/mL = 5 mL bacteriostatic water
• Aliquot: freeze 20 x 250 µL aliquots at -80 °C for long-term storage; thaw individual aliquots as needed, diluting 10-fold to 100 µg/mL working solution for each experimental day.
• For a 250 g rat at 10 µg/kg: use 25 µL of the 100 µg/mL working dilution.

For comprehensive dosage mathematics including molar conversions, body surface area scaling between species, and error analysis, see the dosage calculation guide.

Literature-Reported Research Dose Ranges

The following table summarizes dose ranges described in peer-reviewed publications. These are strictly reference parameters for laboratory protocol design.

Storage After Reconstitution

Reconstituted GHRP-2 in bacteriostatic water is stable at 2-8 °C for up to 28 days based on published stability data for similar hexapeptides. Freeze-thaw cycling degrades peptide integrity; researchers should prepare single-use working aliquots where possible, or use the concentrated stock approach described in Worked Example 3. Avoid prolonged exposure to temperatures above 25 °C, strong light, or alkaline pH, which accelerate tryptophan and naphthylalanine residue oxidation.

Side Effects and Safety

Observed Effects in Preclinical Models

In rodent studies, the principal observations at pharmacologically relevant doses include:

Cortisol and ACTH elevation: At doses producing near-maximal GH responses (above approximately 10 µg/kg IV in rats), ACTH and corticosterone levels rise transiently. This represents a research confound for stress-response studies and must be controlled using appropriate sham-injection groups. ^[5]

Prolactin elevation: Similar to ghrelin itself, GHRP-2 stimulates transient prolactin release through hypothalamic dopaminergic and GHS-R1a pathways. At the doses used in most rodent protocols this rise is modest and transient, but it complicates experiments involving lactation, gonadal axis studies, or any endpoint sensitive to prolactin signaling. ^[5]

Increased food intake: The orexigenic effect through NPY/AgRP pathways is well-documented and represents a true physiological response to GHS-R1a activation rather than a toxicological adverse effect. Researchers must control for caloric intake in body composition studies to distinguish GH-mediated effects from appetite-driven changes. ^[6]

Transient blood pressure changes: At high IV doses in anesthetized rodents, brief hypotensive episodes have been reported in some protocols, attributed to peripheral vasodilation downstream of GH and possible direct vascular GHS-R1a activation. These are transient and not observed at typical SC research doses.

Water retention: GH itself causes sodium and water retention; GHRP-2-induced GH surges in chronic experiments may produce mild body weight increases attributable to fluid retention rather than lean mass accretion in the short term. Careful measurement protocols using dual-energy X-ray absorptiometry (DEXA) or multicompartment body composition models are advisable for body composition studies.

Safety Context from Human Diagnostic Studies

The most extensive human safety data comes from the Japanese pralmorelin diagnostic program and the Ghigo et al. multicenter study. ^[13] Across more than 200 subjects receiving single-dose IV pralmorelin (1 µg/kg), adverse events were mild and self-limiting: facial flushing (12%), transient warmth or tingling (18%), mild nausea (5%). No cardiac arrhythmias, no hypoglycemia, no significant blood pressure changes, and no serious adverse events were reported. These data pertain exclusively to single-dose IV administration in supervised clinical settings and cannot be extrapolated to chronic, unsupervised, or alternative-route administration.

Receptor Desensitization and Tachyphylaxis

Repeated administration of GHRP-2 at short intervals (less than 3 hours between doses in rodent models) produces progressive attenuation of GH response, consistent with GHS-R1a internalization and receptor desensitization. ^[7] This is a relevant experimental design consideration: studies comparing morning and evening GH responses must account for residual receptor desensitization, and washout periods of at least 4-6 hours between doses are standard in literature protocols.

Contaminant and Impurity Risks

Research-grade peptides sourced without rigorous quality verification may contain endotoxin contamination, synthesis byproducts (truncated sequences, N-methylated analogs), or incorrect peptide sequence altogether. Endotoxin in particular produces systemic inflammatory responses in rodents at levels well below what would be detectable without LAL testing, confounding cytokine, immune, and metabolic endpoints. Researchers should request batch-specific CoA documentation and consider independent verification as described in the Purity and Verification section above.

How It Compares

Understanding how GHRP-2 sits within the broader landscape of growth hormone secretagogues helps researchers select the most appropriate tool for their specific experimental question.

Head-to-Head Comparison Discussion

GHRP-2 vs GHRP-6: The most common comparison in the literature, GHRP-2 consistently shows higher GH-releasing potency at equivalent doses, attributed to the D-2-Nal substitution filling the GHS-R1a hydrophobic pocket more efficiently than D-Trp. ^[3] GHRP-6 produces a comparatively greater orexigenic effect relative to its GH-releasing potency, which may be a favorable feature for food intake studies but an experimental confound for body composition work. For experiments where maximal GH pulsatility with minimal appetite confounds is the priority, GHRP-2 is the better choice.

GHRP-2 vs Ipamorelin: Ipamorelin is widely regarded as the most GH-selective synthetic GHS because it produces negligible cortisol, ACTH, or prolactin elevation even at maximal GH-releasing doses. ^[15] This selectivity comes at a moderate cost in peak GH amplitude compared to GHRP-2. For experiments where endocrine confounds must be minimized (immune studies, adrenal models, reproductive research), ipamorelin is often the preferable tool. For experiments specifically requiring the corticotropic or prolactinergic co-stimulation characteristic of GHRP-2, the latter is the appropriate choice.

GHRP-2 vs Hexarelin: Hexarelin is the most potent synthetic hexapeptide in terms of GH release but also produces the greatest cortisol and prolactin elevations and has the additional complexity of CD36 receptor interactions that mediate GH-independent cardiac and adrenocortical effects. ^[16] Research designs requiring clean GHS-R1a pharmacology without CD36 confounds should prefer GHRP-2 or ipamorelin.

GHRP-2 vs MK-677: MK-677 (ibutamoren mesylate) is a non-peptide spiro-indane GHS that achieves oral bioavailability and a 24-hour half-life, producing sustained elevation of GH and IGF-1 over a 24-hour dosing interval. ^[17] This pharmacokinetic profile fundamentally changes the biology: MK-677 promotes non-pulsatile, sustained GH elevation rather than the discrete pulses produced by GHRP-2. For studies modeling the physiological pulsatile GH axis, GHRP-2 is the mechanistically appropriate tool. For studies requiring chronic, stable IGF-1 elevation (e.g., long-term body composition or bone density studies), MK-677 may be operationally simpler.

GHRP-2 combined with GHRH analogs: As described in Svensson et al. (1998), combining GHRP-2 with a GHRH receptor agonist (sermorelin, CJC-1295, native GHRH 1-44) produces supra-additive GH responses. This combination strategy is used in research designs requiring maximal GH secretory challenge tests or when probing the upper limit of somatotroph reserve. ^[8] The combination is mechanistically clean because the two peptides act at completely different receptors with no cross-reactivity.

Open Research Questions

Despite three decades of characterization, several aspects of GHRP-2 biology remain actively contested or under-studied:

Long-term receptor desensitization kinetics in aged animals: Most chronic rodent studies run for 4-8 weeks, which is insufficient to characterize GHS-R1a adaptation over the rodent lifespan. Whether long-term GHRP-2 administration maintains or eventually attenuates GH pulsatility in aging models is incompletely characterized.

Neuroprotective mechanisms: Preliminary in-vitro data suggest GHS-R1a activation in hippocampal and cortical neurons reduces amyloid-beta aggregation and tau phosphorylation through PI3K/Akt pathways. ^[9] However, in-vivo rodent Alzheimer's model studies with GHRP-2 specifically are sparse, and the relative contributions of direct neuronal GHS-R1a signaling versus IGF-1-mediated effects remain unclear.

Sex-specific pharmacodynamics: The clinical literature consistently documents higher GH responses in women than men at equivalent doses, but the mechanistic basis (estrogen-mediated somatotroph sensitization, sex differences in somatostatin tone, or pharmacokinetic differences in distribution volume) has not been definitively resolved for GHRP-2 specifically.

Immune modulation: GHS-R1a expression on macrophages and T-cells has been described, and ghrelin has demonstrable anti-inflammatory effects in sepsis models. Whether GHRP-2 replicates these effects at research doses and whether they are GH-mediated or direct immunomodulatory actions remains an active research area. ^[18]

Gut-brain axis interaction: GHS-R1a is expressed in enteric neurons and vagal afferents, and ghrelin from gastric X/A cells has well-documented gastrointestinal motility effects. GHRP-2's interaction with the enteric GHS-R1a system is largely uncharacterized compared to native ghrelin, and this gap may be relevant for metabolic disease research.

Where to Buy

Apollo Peptide Sciences offers this GHRP-2 Acetate 5 mg vial at $20.00. See our full GHRP-2 Acetate 5mg review page for current availability, batch-specific CoA links, and affiliate-linked purchasing access. Apollo Peptide Sciences is evaluated on our peptide supplier directory for quality documentation practices, customer support, and independent analytical verification frequency.

When comparing vendors, the primary evaluation criteria should be:

1. Batch-specific HPLC chromatogram with identified purity percentage (not just "98%+ typical")
2. Mass spectrometry data confirming identity (not just purity)
3. Endotoxin testing data if in-vivo work is planned
4. Responsiveness to analytical data requests
5. Return / remixing policy for documented purity failures

See our supplier selection guide for a full framework. The disclosure page explains our affiliate relationships and editorial independence policy, and the disclaimer details the research-only status of all compounds listed on this site.

FAQ